BioSpace News Archive

Karuna Therapeutics, Inc. announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, November 16, 2022, at 3:50 p.m. GMT.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced third quarter results and an update on U.S. companion animal diagnostics trends.

Quest Diagnostics announced that Jim Davis has succeeded Steve Rusckowski as the CEO and President of Quest Diagnostics, completing a transition first announced on February 3, 2022.

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain business developments for 5:00 pm ET on Tuesday, November 8, 2022.

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022.

Norstella , a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline a leader in the clinical trial intelligence space.

Sonendo , Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it has received Health Canada regulatory approval for commercial sales of its recently announced GentleWave G4 System.

Axcella Therapeutics today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022.

Xeris Biopharma Holdings, Inc. today announced that the European Journal of Endocrinology (EJE) published the extended evaluation (EE) results of the SONICS study (NCT01838551) evaluating longer-term effects of levoketoconazole on cortisol levels, biomarkers of Cushing’s syndrome (CS) comorbidities.